Tamoxifen: Pioneering medicine in breast cancer

Philipp Y. Maximov; Russell E. McDaniel; V. Craig Jordan

doi:10.1007/978-3-0348-0664-0

Tamoxifen: Pioneering medicine in breast cancer

Philipp Y. Maximov, Russell E. McDaniel, V. Craig Jordan

Research output: Book/Report › Book

19 Scopus citations

Abstract

Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years. This monograph, written by V. Craig Jordan - known as the "father of tamoxifen" - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a "failed morning after contraceptive" to become the "gold standard" for the treatment of breast cancer. He contributed to every aspect of tamoxifen application in therapeutics and all aspects of tamoxifen's pharmacology. He discovered the selective estrogen receptor modulators (SERMs) and explored the new biology of estrogen-induced apoptosis.

Original language	English (US)
Publisher	Springer Basel
Number of pages	199
ISBN (Electronic)	9783034806640
ISBN (Print)	9783034806633
DOIs	https://doi.org/10.1007/978-3-0348-0664-0
State	Published - Jan 1 2013
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-0348-0664-0

Cite this

@book{e61b7712b4cf492ca2d1d0a1f932e838,

title = "Tamoxifen: Pioneering medicine in breast cancer",

abstract = "Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years. This monograph, written by V. Craig Jordan - known as the {"}father of tamoxifen{"} - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a {"}failed morning after contraceptive{"} to become the {"}gold standard{"} for the treatment of breast cancer. He contributed to every aspect of tamoxifen application in therapeutics and all aspects of tamoxifen's pharmacology. He discovered the selective estrogen receptor modulators (SERMs) and explored the new biology of estrogen-induced apoptosis.",

author = "Maximov, {Philipp Y.} and McDaniel, {Russell E.} and Jordan, {V. Craig}",

year = "2013",

month = jan,

day = "1",

doi = "10.1007/978-3-0348-0664-0",

language = "English (US)",

isbn = "9783034806633",

publisher = "Springer Basel",

}

TY - BOOK

T1 - Tamoxifen

T2 - Pioneering medicine in breast cancer

AU - Maximov, Philipp Y.

AU - McDaniel, Russell E.

AU - Jordan, V. Craig

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years. This monograph, written by V. Craig Jordan - known as the "father of tamoxifen" - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a "failed morning after contraceptive" to become the "gold standard" for the treatment of breast cancer. He contributed to every aspect of tamoxifen application in therapeutics and all aspects of tamoxifen's pharmacology. He discovered the selective estrogen receptor modulators (SERMs) and explored the new biology of estrogen-induced apoptosis.

AB - Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years. This monograph, written by V. Craig Jordan - known as the "father of tamoxifen" - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a "failed morning after contraceptive" to become the "gold standard" for the treatment of breast cancer. He contributed to every aspect of tamoxifen application in therapeutics and all aspects of tamoxifen's pharmacology. He discovered the selective estrogen receptor modulators (SERMs) and explored the new biology of estrogen-induced apoptosis.

UR - http://www.scopus.com/inward/record.url?scp=84902528654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902528654&partnerID=8YFLogxK

U2 - 10.1007/978-3-0348-0664-0

DO - 10.1007/978-3-0348-0664-0

M3 - Book

AN - SCOPUS:84902528654

SN - 9783034806633

BT - Tamoxifen

PB - Springer Basel

ER -

Tamoxifen: Pioneering medicine in breast cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this